Advertisement

Topics

AstraZeneca: FDA Grants Orphan Drug Designation For Selumetinib

02:29 EST 15 Feb 2018 | FinanzNachrichten

LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) and Merck & Co., Inc. announced the US FDA has granted Orphan Drug Designation for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromato...

Original Article: AstraZeneca: FDA Grants Orphan Drug Designation For Selumetinib

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca: FDA Grants Orphan Drug Designation For Selumetinib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...